

**NOW**  
FDA cleared for use in adolescents

**TIME  
BEST  
INVENTIONS  
2019**

# Nerivio®


**Easy to use remote electrical neuromodulation (REN) device for acute treatment in episodic and chronic migraine**




**Data from an open-label, single-arm, multicenter, prospective study in adolescents (ages 12-17 years) with migraine.'**

- 45 patients received a device and 39 patients completed at least one evaluable test treatment.
- Total of 159 treatments with Nerivio (pain severity of treated migraines was mostly moderate - 48%).

Single Attack  
Response at 2 hours



Multiple Attacks - Consistency of relief  
Response in at least 50% of treated attacks



#### Safety outcomes:

- Device-related adverse events: 2% (1/45; temporary feeling of pain in the arm).
- Total adverse events: 22% (10/45; all but 1 unrelated to the device).
- No serious device-related adverse events (none of the subjects withdrew due to device-related adverse events).

**INDICATION FOR USE:** Nerivio® is indicated for acute treatment of migraine with or without aura in patients 12 years of age or older. It is a prescription use, self-administered device for use in the home environment at the onset of migraine headache or aura.

**IMPORTANT SAFETY INFORMATION:** Nerivio® should not be used by people with congestive heart failure, severe cardiac or cerebrovascular disease, or uncontrolled epilepsy. Nerivio should not be used by anyone with active implantable medical devices (e.g., pacemaker, hearing aid implant). It should only be applied on the upper arm over dry, healthy skin with normal physical sensation and without any metallic implants or in proximity to cancerous lesions. Nerivio has not been evaluated in pregnancy or those under the age of 12. For full use instructions and safety info, see the Nerivio QuickStart Guide.

#### References:

1. Hershey AD, Lin T, Gruper Y, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents [published online ahead of print, 2020 Dec 21]. *Headache*. 2020;10.1111/head.14042. doi:10.1111/head.14042

Further information: [www.nerivio.com](http://www.nerivio.com)  
Contact: [Nerivio@theranica.com](mailto:Nerivio@theranica.com)

**theranica**